At the 2021 annual meeting of the American Association for Cancer Research (AACR), Zenshine Pharma will presentrecent preclinical and clinical design and studies for its internal research programs, including:
• A phase 1/2a, dose escalation and dose-expansion study of ZX-101A in patients with relapsed/resistant or refractory advanced hematologic malignancies;
• A next-generation PI3Kδ/ϒ inhibitor , ZX-101A inhibiting tumor growth by enhancing anti-tumor immunity;
• Selective PI3Kϒ inhibitor ZX-4081 reprograms the tumor microenvironment to facilitate anti-cancer immunit;
• Potent ENPP1 inhibitors activating STING pathway in tumor microenvironment.
Link of 2021 AACR Annual Meeting: https://www.aacr.org/meeting/aacr-annual-meeting-2021/move-to-virtual-meeting/
